Seeking Alpha

Anika’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study

Study Demonstrated Superiority of Cingal, a Single-Injection Hyaluronic Acid-Based Viscosupplement Combined with Fast-Acting Steroid, Over Steroid Alone, for Osteoarthritis Pain Relief at 26 Weeks ...
News Medical

Anika Therapeutics announces positive results from CINGAL phase 3 trial for knee osteoarthritis

Anika Therapeutics, Inc., (NASDAQ: ANIK), a leader in products for tissue protection, healing, and repair based on hyaluronic acid (HA) technology, today reported positive results from the CINGAL ® 13 ...
Business Wire

Anika Therapeutics Announces Decision to Proceed with CINGAL® Premarket Review Through FDA’s Center for Drug Evaluation and Research

BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ...
Yahoo Finance

Anika Therapeutics Cingal Tops Steroid For Osteoarthritis Pain Relief

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Healio

Anika Therapeutics obtains CE mark for Cingal to treat OA knee pain

Please provide your email address to receive an email when new articles are posted on . Anika Therapeutics Inc. announced it has received CE mark approval for Cingal, reportedly the first and only ...
Business Wire

Anika Therapeutics Announces Top-Line Results from CINGAL 16-02 Clinical Trial in Knee Osteoarthritis

BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary ...
Investing

Anika Reports Top Line Data From CINGAL Study, Shares Slump

Shares of Anika Therapeutics Inc (NASDAQ:ANIK) slumped 37% after the company reported disappointing data from its phase III Cingal 16-02 study. The 16-02 trial compared Cingal, a combination of ...

Has your knee pain become impossible to ignore?

Knee osteoarthritis is one of the most common causes of chronic pain and disability. Women are affected more than men, and ...
The Motley Fool

2 Biotech Stocks That Tanked This Week: Can They Recover?

This biotech stock lost around a third of its value after its knee injection for arthritis missed the mark during an important clinical trial. Cingal is already marketed in the EU, but the Food and ...
Mena FN

Anika's Cingal® Successfully Achieves Primary Endpoint In Third Phase III Study

Study Demonstrated Superiority of Cingal, a Single-Injection Hyaluronic Acid-Based Viscosupplement Combined with Fast-Acting Steroid, Over Steroid Alone, for Osteoarthritis Pain Relief at 26 Weeks ...
streetinsider

Anika's (ANIK) Cingal Achieves Primary Endpoint in Third Phase III Study

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on ...